Emerging Issues in First-line Antiretroviral Therapy
Source: Emerging Issues in First-line Antiretroviral Therapy

Interactive Video Module

Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, review timing and choice of first-line antiretroviral therapy in this unique program with a didactic video module and several case-based vignettes in which you are invited to help manage the patient.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Employ evidence-based decisions regarding timing and choice of first-line antiretroviral regimens
  • Compare and contrast the benefits of different antiretroviral regimen choices for individual patients, taking into account coinfection or pregnancy
  • Interpret the most recent data in treatment decisions for HIV-infected patients initiating antiretroviral therapy
 

Faculty

  • Joel E. Gallant
    MD, MPH
    Charles B. Hicks
    MD

Credit Information

  • Release Date:
    April 13, 2012
  • Expiration Date:
    April 12, 2013
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Faculty

Joel E. Gallant, MD, MPH


Professor of Medicine and Epidemiology
Associate Director, Johns Hopkins AIDS Service
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Joel E. Gallant, MD MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, RAPID Pharmaceuticals, and Sangamo Biosciences.
 

Charles B. Hicks, MD


Professor of Medicine
Director and Principal Investigator
Interdisciplinary Research Training Program in AIDS
Division of Infectious Diseases
Duke University Medical Center
Durham, North Carolina

Charles B. Hicks, MD, has disclosed that he has received consulting fees and funding for research support from Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV and consulting fees from Argos.
 

Staff

Elaine P. Seeskin, 


Senior Managing Editor

Elaine P. Seeskin has no significant financial relationships to disclose.
 

Edward King, MA


Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no significant financial relationships to disclose.
 

Jennifer M. Blanchette, PhD


Associate Managing Editor

Jennifer M. Blanchette, PhD, has no significant financial relationships to disclose.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; Patricia Staples, MSN, NP-C, CCRN and Gordon West, PhD, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This activity is intended for physicians and other healthcare professionals who are involved in the treatment of HIV-infected patients.


Goal

The goal of this activity is to equip participants to make evidence-based decisions regarding the timing and choice of antiretroviral agents in first-line therapy regimens for HIV-infected patients incorporating recently reported data.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Employ evidence-based decisions regarding timing and choice of first-line antiretroviral regimens
  • Compare and contrast the benefits of different antiretroviral regimen choices for individual patients, taking into account coinfection or pregnancy
  • Interpret the most recent data in treatment decisions for HIV-infected patients initiating antiretroviral therapy
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from Janssen Therapeutics, and Gilead Sciences.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 13, 2012, through April 12, 2013:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.